Approval · Notice of Compliance 19084 · 2017
PRIMAQUINE: Notice of Compliance 19084
Issued March 15, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19084
- Date
- March 15, 2017
- Company
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the product monograph (pm) with new dosing recommendation in patients with mild or moderate glucose-6-phosphate dehydrogenase (g6pd) deficiency
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PRIMAQUINE | Not yet assigned | — |
Medicinal ingredients
- PRIMAQUINE PHOSPHATE 26.3 MG per TAB